LivaNova PLC

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -79.42 M102.54 M69.92 M74.91 M183.04 M254.34 M 254.34 M Mittelzufluss aus Investitionstätigkeit -41.84 M36.9 M-38.41 M-40.33 M-48.16 M-72.91 M -72.91 M Zahlungsströme aus der Finanzierungstätigkeit 310.76 M-181.48 M280.13 M21.48 M18.55 M-285.66 M -285.66 M Freier Cashflow -114.45 M77.07 M43.4 M39.93 M135.93 M173.29 M 173.29 M

LivaNova, plc is a medical device manufacturer that is a foreign domiciled company based in the U.K. for tax inversion purposes. With operational headquarters in the United States. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".

LIVN

Financials

LivaNova PLC

Nachrichten

LivaNova Expands OSA Care With FDA-Approved aura6000 System

LivaNova: FDA-Zulassung für Schlafapnoe-Gerät treibt Aktie an

Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?

Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026

NPCE RNS System Explained: Growth Drivers and Setup for 2026

NeuroPace's Seizure ID and New Indication Could Expand RNS Demand

All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy

LivaNova: Excellent Performer Too Expensive In 2026 (Rating Downgrade) (NASDAQ:LIVN)

LivaNova stock hits 52-week high at $71.00

Livanova: Wolfe Research erhöht Kursziel aufgrund positiver Epilepsie-Aussichten

Wolfe Research raises Livanova stock price target on epilepsy outlook

Stifel hebt Kursziel für Livanova nach starkem Wachstum auf 80 US-Dollar an